Boston Scientific's defib woes boost St. Jude Medical's Q1 results

April 21, 2010 by MedCity News

First-quarter sales for St. Jude Medical Inc. got a boost from Boston Scientific Corp.'s shutdown of its defibrillator operations, with STJ officials estimating an up to $25 million sales gain from its competitor's problems.

MedCity News logo

By Thomas Lee

There’s no love lost between St. Jude Medical Inc. (NYSE:STJ) and Boston Scientific Corp. (NYSE:BSX). The two rivals have clashed over sales and salespeople.

So it’s no surprise that St. Jude officials invented a special phrase to describe its competitor’s most recent regulatory woes: “the Boston Debacle.”

Get the complete picture with a MassDevice Plus membership. Registered users can login here.